Bladder Cancer Advocacy Network

Open access article in @Nature: Trends in the use and efficacy of adjuvant immunotherapy in muscle-invasive urothelial carcinoma. Click to read the article: nature.com/articles/s4159…

The BCAN Think Tank meeting (#BCANTT25) kicks off one week from today in Washington, DC. Are your bags packed?

In this @UrologyTimes video, @hjwang26 and @LauraBukavinaMD of @CleClinicUro discuss ctDNA's role in NMIBC treatment decisions. Click here to watch the video: urologytimes.com/view/betty-wan…

Video in @UrologyTimes: Optimizing NMIBC Treatment Through Sequencing and Patient Preference with @marktysonmd @BogdanaSchmidt Sheryas Joshi MD and co-authored by @tbivala1. Click to watch the video: urologytimes.com/view/current-s…

In @OncLive.com: Dr. Yair Lotan on Guideline-Supported Treatment Decision-Making for NMIBC. Click to watch the video: onclive.com/view/dr-lotan-…

J&J receives @US_FDA Priority Review for TAR-200 in high-risk NMIBC Phase 2b SunRISe-1 study #AUA25 ✅82.4 % CR rate ☑️ 52.9 % cancer-free at least one year after CR jnj.com/media-center/p…

@UrogerliMD with elegant IIT of crestimogene intravesical retroviral treatments driving some pathologic CRs & correlative studies of T cell expansion, tertiary lymphoid maturation, & systemic responses. @ANZUPtrials #ANZUP25

Summary in @UroToday: An evidence gap map of the personalized medicine in bladder cancer. Click to read the brief summary: urotoday.com/recent-abstrac….

Panel video in @UrologyTimes with @marktysonmd, @BogdanaSchmidt and Shreyas Joshi MD: The Growing Call for Combination Therapy in NMIBC Treatment. Click here to watch the video: urologytimes.com/view/the-growi…

In @sciencedirect: LncRNA SLC7A11-AS1 suppresses the ferroptosis of bladder cancer cells through regulating SLC7A11 by IGF2BP1 via m6A modification. Click to read the full-text article: sciencedirect.com/science/articl…

Summary in @Urotoday: Impact of timing of computed tomography staging and patient factors on the detection of 'true' cN+ bladder cancer. Click here to read more: urotoday.com/recent-abstrac…

Long-term follow-up report on salvage sequential intravesical Valrubicin and Docetaxel (Val/Doce) - High-Risk cohort (44% BCG-unresponsive, 96% Gem/Doce unresponsive, 20% prostatic urethral involvement) - 1y RFS 58% - 5y PFS 70% - 1% G3+ AEs Needs prospective eval! @eaonc

In @biomedcentral (full text): Smoking promotes the progression of bladder cancer through FOXM1/CKAP2L axis. Click to read the article: …nslational-medicine.biomedcentral.com/articles/10.11…

From PubMed at @NLM_NIH: The role of DNA methylation and demethylation in bladder cancer: a focus on therapeutic strategies. Click here to read the article: pubmed.ncbi.nlm.nih.gov/40641934/

Registry data shows risk migration with blue light cystoscopy. @alirezaghoreifi @DukeUrology & @siadaneshmand @KECKSchool_USC sit down with @UroDocAsh @MDAndersonNews to highlight the blue light cystoscopy registry's value as an ongoing real-world database with over 3,000…

Deeply grateful to BCAN for this incredible honor receiving the YIA! Truly fortunate to be trained by the best @FaltasLab ! Grateful for support from @WCMDeptofMed @WCMGUcancer & collaboration with @WCMEnglanderIPM @nygenome Excited to be part of advancing bladder cancer research

Dr. Andrew Hsieh from @UWMedicine has received a 2025 Bladder Cancer Research Innovation Award from @BladderCancerUS. 🤩 These prestigious $300,000 awards honor exceptional researchers. Congratulations Dr. Hsieh! bit.ly/4lorm0k

Please join us in congratulating @HsiehLab of @FredHutch for this 2025 Bladder Cancer Research Innovation Award. Dr. Hsieh’s research aims to uncover how mutations in other commonly altered genes contribute to diversity in BC. Click here to learn more: bcan.org/bcan-awards-60…